Health Care Equipment

MEDLANDER

MEDLANDER released FY2026 Q1 earnings on April 15 After-Market BJT, actual revenue CNY 99.2 M, actual EPS CNY 0.2344

MEDLANDER FY2026 Q1 Earnings Release on April 16 After-Market (BJT)

MEDLANDER to Release FY2025 Earnings on April 16 Pre-Market (BJT), Forecast Revenue CNY 722 M, EPS CNY 2.3

MEDLANDER released FY2025 earnings on February 26 Pre-Market (BJT), actual revenue CNY 431.59 M (forecast CNY 722 M), actual EPS CNY 1.0492 (forecast CNY 2.3)

MEDLANDER released FY2025 Q4 earnings on February 26 Pre-Market (BJT), actual revenue CNY 87.75 M, actual EPS CNY 0.0678

MEDLANDER released FY2025 Q3 earnings on October 22 During-Market (BJT), actual revenue CNY 102.63 M, actual EPS CNY 0.3281

MEDLANDER released FY2025 9 Months earnings on October 22 During-Market (BJT), actual revenue CNY 343.85 M, actual EPS CNY 0.9812

MEDLANDER to release FY2025 Q3 earnings report on October 23, during market hours (BJT)

MEDLANDER released FY2025 Semi-Annual earnings on August 26 After-Market (BJT), actual revenue CNY 241.22 M, actual EPS CNY 0.6532

MEDLANDER released FY2025 Q2 earnings on August 26 After-Market (BJT), actual revenue CNY 122.94 M, actual EPS CNY 0.2458

MEDLANDER FY2025 Semi-Annual Earnings Release on August 27, 2025 (BJT)

Huayuan Securities Gives Maleda Buy Rating

Meilan De's Q1 Revenue in 2025 Stands at 118 Million Yuan

Maled Release 2024 Annual Report

MEDLANDER released FY2025 Q1 earnings on April 23 After-Market BJT, actual revenue CNY 118.28 M, actual EPS CNY 0.4073

MEDLANDER to Release FY2025 Q1 Earnings on April 24 After-Market BJT

MEDLANDER to release FY2024 earnings on April 24, 2025 (BJT), forecasted revenue CNY 568 M, EPS CNY 1.67

MilanDe Discloses Four Core Business Lines and Market Customer Groups

MEDLANDER released FY2024 earnings on February 26 (BJT), actual revenue CNY 424.55 M (forecast CNY 568 M), actual EPS CNY 1.0309 (forecast CNY 1.67)

MEDLANDER released FY2024 Q4 earnings on February 26, 2025 (BJT) with actual revenue of CNY 93.97 M and EPS of CNY 0.0563

688273

MEDLANDER announced at its investor relations event on May 18, 2026, that it will upgrade its "Women's Health and Beauty" strategy to "Holistic Treatment," focusing on the application of brain-machine interface technology in areas such as mental regulation, motor function reconstruction, and cognitive intervention. At the same time, the company plans to promote the construction of anti-aging centers in public hospitals, expand new scenarios in urology and andrology, drive technological commercialization, and enhance market competitiveness

同壁财经

PACIFIC SECURITIES

CITIC Securities Co., Ltd.

CITIC SEC

MEDLANDER iterates its "brain-computer interface + mind-body integration" strategy to broaden growth boundaries through multi-business collaboration

ASMG

159546

ASML

561980

159995

159516

588200

ASML CFO: The company is surprised by the strong demand in the Chinese market for 2025

Wallstreetcn

Leverage Shares 2X Long ASML Daily ETF

Guotai CSI All Share Integrated Circuit ETF

MEGA P&C

Harvest CSI All Share Integrated Circuit ETF

Guotai CSI Subdivision Mechanical Equipment Industry Theme ETF

China Merchants CSI Semiconductor Industry ETF

ChinaAMC Guozheng Semiconductor Chip ETF

Guotai CSI Semiconductor Material Equipment Theme ETF

Motic Electric

Harvest SSE STAR Chip ETF

E Fund CSI Semiconductor Material & Equipment Thematic ETF

SOXX

ASML CEO: The company can become more "flexible."

iShares Semiconductor ETF

VanEck Semiconductor ETF

ASML expects a gross margin of 51% to 53% in 2026, with an estimate of 52.9%. ASML announced that it will repurchase up to €12 billion worth of shares by the end of 2028. Risk warning and disclaimer: The market has risks, and investment should be cautious. This article does not constitute personal investment advice and does not take into account the specific investment goals, financial situation, or needs of individual users. Users should consider whether any opinions, views, or conclusions in this article align with their specific circumstances. Investment based on this is at one's own risk

ASML's fourth-quarter net sales reached €9.72 billion, expected €9.57 billion

MEDLANDER announced that the company will review the profit distribution plan at the third extraordinary general meeting of shareholders in 2025, proposing to distribute a cash dividend of 3 yuan for every 10 shares, totaling 29.3424 million yuan. At the same time, the company plans to change its registered address to No. 1 Hualin Road, Jiangning District, Nanjing, and revise the "Articles of Association."

Zhitong

MEDLANDER: Plans to distribute nearly 30 million in dividends for the first three quarters and change its registered address

MEDLANDER released its third-quarter report for 2025, with revenue of 344 million yuan in the first three quarters, a year-on-year increase of 4.01%; net profit attributable to shareholders of 95.9987 million yuan, a year-on-year decrease of 0.07%; net profit excluding non-recurring gains and losses of 79.8 million yuan, a year-on-year decrease of 9.74%; basic earnings per share of 0.9813 yuan. The company plans to distribute a cash dividend of 3.00 yuan (including tax) for every 10 shares to all shareholders

MEDLANDER released its performance for the first three quarters, with a net profit attributable to the parent company of 95.9987 million yuan, a year-on-year decrease of 0.07%

MEDLANDER announced that it achieved a net profit of 95.9987 million yuan in the first three quarters of 2025 and plans to distribute a cash dividend of 3 yuan for every 10 shares to all shareholders, totaling a cash dividend of 29.3424 million yuan. The company will not convert reserves into share capital or issue bonus shares, with a total of 97.8079 million shares participating in the dividend. This plan needs to be submitted for review at the third extraordinary general meeting of shareholders in 2025

MEDLANDER plans to distribute 29.3424 million yuan in cash in the first three quarters of 2025, with no bonus shares or stock dividends

688767

301330

688626

In a recent earnings briefing, several A-share listed companies, including Xiangyu Medical, MEDLANDER, BIOTEST BIOTECH, and ZKTECO, disclosed the latest developments in brain-computer interface technology. Some companies expect to achieve revenue within the year, launch new products, and seize development opportunities through investment layouts. In the second half of the year, relevant companies will accelerate investment and product implementation, and local policies will also support commercialization, driving the brain-computer interface industry into a new phase

BIOTEST BIOTECH

ZKTECO

Xiangyu Medical

Multiple A-share companies reveal progress and product updates in brain-computer interface technology

On the evening of August 26, MEDLANDER disclosed its 2025 semi-annual report, achieving operating revenue of 241 million yuan in the first half of the year, a year-on-year increase of 5.62%; net profit attributable to the parent company was 63.9201 million yuan, a year-on-year decrease of 11.96%; basic earnings per share were 0.6532 yuan

MEDLANDER: Net profit for the first half of the year was 63.9201 million yuan, a year-on-year decrease of 11.96%

688580

688212

The medical equipment sector has seen a short-term decline, with MEDLANDER falling over 7%. Xiangyu Medical, AOHUA ENDOSCOPY, Lude Medical, VISHEE, and others have also followed suit

VISHEE

AOHUA ENDOSCOPY

The medical equipment sector has declined in the short term, with MEDLANDER falling over 7%

MEDLANDER(688273.SH)